Mechanism of Antiviral Activity of Nitazoxanide against the Influenza Virus: Effect of Tizoxanide on AdenosineTriphosphate in Influenza-virus Infected Madin Darby Canine Kidney Cells
Abstract
BackgroundNitazoxanide (NTZ) is a broad-spectrum antiviral undergoing clinical development for treating influenza and other viral respiratory infections such as those caused by rhinovirus/enterovirus and coronavirus including the emerging SARS-CoV-2. MethodsNitazoxanide is a mild uncoupler of oxidative phosphorylation, which is modulating the ATP production in cells. ATP is an essential component of viral replication, and we have evaluated the effect of tizoxanide (TIZ), the active circulating metabolite of NTZ, on ATP in Madin-Darby canine kidney (MDCK) cells and in MDCK cells infected with influenza A and B viruses. ResultsTIZ decreased cellular ATP in a dose-dependent manner in MDCK cells and in MDCK cells infected with influenza A and B viruses. Maximum inhibition of ATP in influenza infected or uninfected MDCK cells reached up to 45% after 6 and 24 hours of exposure to 100{micro}M TIZ. The decrease in cellular ATP did not affect cell viability and was reversible after eliminating TIZ from the culture. ConclusionThe concentrations of TIZ required to decrease cellular ATP levels were similar to those reported to inhibit replication of influenza A and B viruses in our laboratory. A decrease in ATP triggers activation of AMP-activated protein kinase, which is known to suppress the secretion of pro-inflammatory cytokines. Additional studies are warranted to evaluate the effect of TIZ on mitochondrial function.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antiviral effect of thiazolides relies on mitochondrial mild uncoupling
N. Hammad, C. Ransy, … J.-F. Rossignol·bioRxiv·Sep 16, 2022
- NAD metabolism plays multiple roles in influenza A virus replication in a novel ex vivo model of mouse lung infection.
Florentine Jacolin, Anne Aublin‐Gex, … Laure Perrin‐Cocon·bioRxiv·Oct 14, 2025
- Old drugs with new tricks: Efficacy of fluoroquinolones to suppress replication of flaviviruses
S. L. P. Scroggs, C. C. Andrade, … S. L. Rossi·bioRxiv·Mar 30, 2020
- Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection
A. Sohail, A. Iqbal, … F. Pessler·bioRxiv·Jan 20, 2021
- Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy.
B. S. Pollard, J. C. Blanco, … G. A. Prince·bioRxiv·Apr 9, 2020
- NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner
F. H. Waqas, M. Shehata, … F. Pessler·bioRxiv·Jun 11, 2023